Bunin GR, Surawicz TS, Witman PA, Preston-Martin S, Davis F, Bruner JM. The descriptive epidemiology of craniopharyngioma. J Neurosurg. 1998;89:547–51.

CAS  PubMed  Google Scholar 

Sterkenburg AS, Hoffmann A, Gebhardt U, Warmuth-Metz M, Daubenbüchel AMM, Müller HL. Survival, hypothalamic obesity, and neuropsychological/psychosocial status after childhood-onset craniopharyngioma: newly reported long-term outcomes. Neuro Oncol. 2015;17:1029–38.

PubMed  PubMed Central  Google Scholar 

Duff JM, Meyer FB, Ilstrup DM, Laws ER, Schleck CD, Scheithauer BW. Long-term outcomes for surgically resected craniopharyngiomas. Neurosurgery. 2000;46:291–305.

CAS  PubMed  Google Scholar 

Dekkers OM, Biermasz NR, Smit JWA, Groot LE, Roelfsema F, Romijn JA, et al. Quality of life in treated adult craniopharyngioma patients. Eur J Endocrinol. 2006;154:483–9.

CAS  PubMed  Google Scholar 

Kleihues P, Louis DN, Scheithauer BW, Rorke LB, Reifenberger G, Burger PC, et al. The WHO classification of tumors of the nervous system. J Neuropathol Exp Neurol. 2002;61:215–25 (discussion 226–9).

PubMed  Google Scholar 

Louis DN, Ohgaki H, Wiestler OD, Cavenee WK, Burger PC, Jouvet A, et al. The 2007 WHO classification of tumours of the central nervous system. Acta Neuropathol. 2007;114:97–109.

PubMed  PubMed Central  Google Scholar 

Kleihues P, Burger PC, Scheithauer BW. The new WHO classification of brain tumours. Brain Pathol. 1993;3:255–68.

CAS  PubMed  Google Scholar 

Zülch KJ. Principles of the new World Health Organization (WHO) classification of brain tumors. Neuroradiology. 1980;19:59–66.

PubMed  Google Scholar 

Louis DN, Perry A, Reifenberger G, von Deimling A, Figarella-Branger D, Cavenee WK, et al. The 2016 World Health Organization classification of tumors of the central nervous system: a summary. Acta Neuropathol. 2016;131:803–20.

PubMed  Google Scholar 

Louis DN, Perry A, Wesseling P, Brat DJ, Cree IA, Figarella-Branger D, et al. The 2021 WHO classification of tumors of the central nervous system: a summary. Neuro Oncol. 2021;23:1231–51.

CAS  PubMed  PubMed Central  Google Scholar 

An W, Li S, An Y, Lin Z. Molecular subtypes of adamantinomatous craniopharyngiomas. Neuro Oncol. 2025;27(5):1180–92.

PubMed  PubMed Central  Google Scholar 

Brastianos PK, Taylor-Weiner A, Manley PE, Jones RT, Dias-Santagata D, Thorner AR, et al. Exome sequencing identifies BRAF mutations in papillary craniopharyngiomas. Nat Genet. 2014;46:161–5.

CAS  PubMed  PubMed Central  Google Scholar 

Zhao C, Zhou Z, Zhang Y, Qi X, Wang X, Lin D, et al. Diagnosis and management of pediatric papillary craniopharyngiomas. World Neurosurg. 2022;165:e148–58.

PubMed  Google Scholar 

Takagi K, Kikuchi K, Hiwatashi A, Togao O, Sangatsuda Y, Kuga D, et al. Papillary craniopharyngioma coexisting with an intratumoral abscess in a pediatric patient: a case report and review of the literature. Acta Radiol Open. 2021;10:205846012110306.

Google Scholar 

Hölsken A, Sill M, Merkle J, Schweizer L, Buchfelder M, Flitsch J, et al. Adamantinomatous and papillary craniopharyngiomas are characterized by distinct epigenomic as well as mutational and transcriptomic profiles. Acta Neuropathol Commun. 2016;4:20.

PubMed  PubMed Central  Google Scholar 

Goschzik T, Gessi M, Dreschmann V, Gebhardt U, Wang L, Yamaguchi S, et al. Genomic alterations of adamantinomatous and papillary craniopharyngioma. J Neuropathol Exp Neurol. 2017;76:126–34.

CAS  PubMed  Google Scholar 

Wang X, Zhao C, Lin J, Liu H, Zeng Q, Chen H, et al. Multi-omics analysis of adamantinomatous craniopharyngiomas reveals distinct molecular subgroups with prognostic and treatment response significance. Chin Med J (Engl). 2023;137:859–70.

PubMed  Google Scholar 

Gunderwala A, Cope N, Wang Z. Mechanism and inhibition of BRAF kinase. Curr Opin Chem Biol. 2022;71:102205.

CAS  PubMed  PubMed Central  Google Scholar 

Maloney RC, Zhang M, Liu Y, Jang H, Nussinov R. The mechanism of activation of MEK1 by B-Raf and KSR1. Cell Mol Life Sci. 2022;79:281.

CAS  PubMed  PubMed Central  Google Scholar 

Blakeley JO, Shannon K. Precision oncology for papillary craniopharyngioma. N Engl J Med. 2023;389:179–81.

PubMed  Google Scholar 

Cantwell-Dorris ER, O’Leary JJ, Sheils OM. BRAFV600E: implications for carcinogenesis and molecular therapy. Mol Cancer Ther. 2011;10:385–94.

CAS  PubMed  Google Scholar 

Bahar ME, Kim HJ, Kim DR. Targeting the RAS/RAF/MAPK pathway for cancer therapy: from mechanism to clinical studies. Signal Transduct Target Ther. 2023;8:455.

CAS  PubMed  PubMed Central  Google Scholar 

Haston S, Pozzi S, Carreno G, Manshaei S, Panousopoulos L, Gonzalez-Meljem JM, et al. MAPK pathway control of stem cell proliferation and differentiation in the embryonic pituitary provides insights into the pathogenesis of papillary craniopharyngioma. Development. 2017;144:2141–52.

CAS  PubMed  PubMed Central  Google Scholar 

Mu W, Li S, Xu J, Guo X, Wu H, Chen Z, et al. Hypothalamic Rax+ tanycytes contribute to tissue repair and tumorigenesis upon oncogene activation in mice. Nat Commun. 2021;12:2288.

CAS  PubMed  PubMed Central  Google Scholar 

Clasadonte J, Prevot V. The special relationship: glia-neuron interactions in the neuroendocrine hypothalamus. Nat Rev Endocrinol. 2017;14:25–44.

PubMed  Google Scholar 

Korf H-W, Møller M. Arcuate nucleus, median eminence, and hypophysial pars tuberalis. Handb Clin Neurol. 2021;180:227–51.

PubMed  Google Scholar 

Prevot V, Nogueiras R, Schwaninger M. Tanycytes in the infundibular nucleus and median eminence and their role in the blood–brain barrier. Handb Clin Neurol. 2021;180:253–73.

PubMed  Google Scholar 

Rodríguez EM, Blázquez JL, Guerra M. The design of barriers in the hypothalamus allows the median eminence and the arcuate nucleus to enjoy private milieus: the former opens to the portal blood and the latter to the cerebrospinal fluid. Peptides. 2010;31:757–76.

PubMed  Google Scholar 

Prieto R, Juratli TA, Bander ED, Santagata S, Barrios L, Brastianos PK, et al. Papillary craniopharyngioma: an integrative and comprehensive review. Endocr Rev. 2024;46:151–213.

Google Scholar 

Coy S, Rashid R, Lin J-R, Du Z, Donson AM, Hankinson TC, et al. Multiplexed immunofluorescence reveals potential PD-1/PD-L1 pathway vulnerabilities in craniopharyngioma. Neuro Oncol. 2018;20:1101–12.

CAS  PubMed  PubMed Central  Google Scholar 

Chen C, Wang Y, Zhong K, Jiang C, Wang L, Yuan Z, et al. Frequent B7–H3 overexpression in craniopharyngioma. Biochem Biophys Res Commun. 2019;514:379–85.

CAS  PubMed  Google Scholar 

Tang M, Chen C, Wang G, Wang Y, Zhang Z, Li H, et al. Evaluation of B7–H3 targeted immunotherapy in a 3D organoid model of craniopharyngioma. Biomolecules. 2022;12:1744.

CAS  PubMed  PubMed Central  Google Scholar 

Jia Y, Ma L, Cai K, Zhang B, Wu W, Xiao Y, et al. Immune infiltration in aggressive papillary craniopharyngioma: high infiltration but low action. Front Immunol. 2022;13:995655.

CAS  PubMed  PubMed Central  Google Scholar 

Lin D, Wang Y, Zhou Z, Lin Z. Immune microenvironment of primary and recurrent craniopharyngiomas: a study of the differences and clinical significance. World Neurosurg. 2019;127:e212–20.

PubMed  Google Scholar 

Matson DD, Crigler JF. Management of craniopharyngioma in childhood. J Neurosurg. 1969;30:377–90.

CAS  PubMed  Google Scholar 

Hoffman HJ, Silva MD, Humphreys RP, Drake JM, Smith ML, Blaser SI. Aggressive surgical management of craniopharyngiomas in children. J Neurosurg. 1992;76:47–52.

CAS  PubMed  Google Scholar 

Yaşargil MG, Curcic M, Kis M, Siegenthaler G, Teddy PJ, Roth P. Total removal of craniopharyngiomas. J Neurosurg. 1990;73:3–11.

PubMed  Google Scholar 

Maira G, Anile C, Rossi GF, Colosimo C. Surgical treatment of craniopharyngiomas. Neurosurgery. 1995;36:715–24.

CAS  PubMed  Google Scholar 

Sweet WH. Radical surgical treatment of craniopharyngioma. Neurosurgery. 1976;23:52–79.

CAS  Google Scholar 

Piloni M, Gagliardi F, Bailo M, Losa M, Boari N, Spina A, et al. Craniopharyngioma in pediatrics and adults. In: Sex Gend Factor Affect Metab Homeost Diabetes Obes. Cham: Springer International Publishing; 2023. p. 299–329.